These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 23562240)

  • 1. Learning from our mistakes: the 'unknown knowns' in fragment screening.
    Davis BJ; Erlanson DA
    Bioorg Med Chem Lett; 2013 May; 23(10):2844-52. PubMed ID: 23562240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introduction to fragment-based drug discovery.
    Erlanson DA
    Top Curr Chem; 2012; 317():1-32. PubMed ID: 21695633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complementarity between in silico and biophysical screening approaches in fragment-based lead discovery against the A(2A) adenosine receptor.
    Chen D; Ranganathan A; IJzerman AP; Siegal G; Carlsson J
    J Chem Inf Model; 2013 Oct; 53(10):2701-14. PubMed ID: 23971943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fragment screening using X-ray crystallography.
    Davies TG; Tickle IJ
    Top Curr Chem; 2012; 317():33-59. PubMed ID: 21678136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent progress in fragment-based lead discovery.
    Schulz MN; Hubbard RE
    Curr Opin Pharmacol; 2009 Oct; 9(5):615-21. PubMed ID: 19477685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fragment-based approaches in drug discovery and chemical biology.
    Scott DE; Coyne AG; Hudson SA; Abell C
    Biochemistry; 2012 Jun; 51(25):4990-5003. PubMed ID: 22697260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HTS by NMR of combinatorial libraries: a fragment-based approach to ligand discovery.
    Wu B; Zhang Z; Noberini R; Barile E; Giulianotti M; Pinilla C; Houghten RA; Pasquale EB; Pellecchia M
    Chem Biol; 2013 Jan; 20(1):19-33. PubMed ID: 23352136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the design of a multipurpose fragment screening library.
    Wilde F; Link A
    Expert Opin Drug Discov; 2013 May; 8(5):597-606. PubMed ID: 23480068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining biophysical screening and X-ray crystallography for fragment-based drug discovery.
    Hennig M; Ruf A; Huber W
    Top Curr Chem; 2012; 317():115-43. PubMed ID: 21837555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fragment-based lead discovery from smaller fragments to functional ligand].
    Hatayama A; Habashita H
    Tanpakushitsu Kakusan Koso; 2009 Sep; 54(12 Suppl):1611-6. PubMed ID: 21089596
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficient search of chemical space: navigating from fragments to structurally diverse chemotypes.
    Wassermann AM; Kutchukian PS; Lounkine E; Luethi T; Hamon J; Bocker MT; Malik HA; Cowan-Jacob SW; Glick M
    J Med Chem; 2013 Nov; 56(21):8879-91. PubMed ID: 24117015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case.
    Kogej T; Blomberg N; Greasley PJ; Mundt S; Vainio MJ; Schamberger J; Schmidt G; Hüser J
    Drug Discov Today; 2013 Oct; 18(19-20):1014-24. PubMed ID: 23127858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragment library design: using cheminformatics and expert chemists to fill gaps in existing fragment libraries.
    Kutchukian PS; So SS; Fischer C; Waller CL
    Methods Mol Biol; 2015; 1289():43-53. PubMed ID: 25709032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel trends in high-throughput screening.
    Mayr LM; Bojanic D
    Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads.
    Bergsdorf C; Ottl J
    Expert Opin Drug Discov; 2010 Nov; 5(11):1095-107. PubMed ID: 22827747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of BRD4 bromodomain inhibitors by fragment-based high-throughput docking.
    Zhao H; Gartenmann L; Dong J; Spiliotopoulos D; Caflisch A
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2493-6. PubMed ID: 24767840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using computational techniques in fragment-based drug discovery.
    Desjarlais RL
    Methods Enzymol; 2011; 493():137-55. PubMed ID: 21371590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors.
    Wyss DF; Wang YS; Eaton HL; Strickland C; Voigt JH; Zhu Z; Stamford AW
    Top Curr Chem; 2012; 317():83-114. PubMed ID: 21647837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancements of screening collections to address areas of unmet medical need: an industry perspective.
    Drewry DH; Macarron R
    Curr Opin Chem Biol; 2010 Jun; 14(3):289-98. PubMed ID: 20413343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligand specificity, privileged substructures and protein druggability from fragment-based screening.
    Barelier S; Krimm I
    Curr Opin Chem Biol; 2011 Aug; 15(4):469-74. PubMed ID: 21411360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.